Zydus Lifesciences: Sentynl Therapeutics Gets FDA Acceptance for CUTX-101 NDA

Zydus Lifesciences announced that Sentyln Therapeutics has received FDA acceptance for the resubmission of its New Drug Application (NDA) for CUTX-101, intended to treat Menkes disease in pediatric patients. The FDA has assigned January 14, 2026 as the new PDUFA Target Action Date for the resubmission.

Regulatory Timeline and Acceptance Details

The FDA accepted the resubmission as a Class I response, marking a significant milestone in the approval process for CUTX-101. Sentyln resubmitted its revised NDA on November 14, 2025 after receiving a complete response letter (CRL) from the FDA on September 30, 2025.

Regulatory Milestone:	Date
CRL Received:	September 30, 2025
NDA Resubmission:	November 14, 2025
FDA Acceptance:	December 15, 2025
PDUFA Target Date:	January 14, 2026

Complete Response Letter Analysis

The CRL cited observations regarding the manufacturing sites cGMP compliance but did not identify any other approvability concerns. Importantly, the FDA found no deficiencies in CUTX-101's efficacy and safety data, which demonstrate improvement in overall survival for Menkes disease subjects who received early treatment with the therapy.

CUTX-101 Clinical Efficacy Data

CUTX-101 is an investigational copper histidinate candidate that showed statistically significant improvement in overall survival for Menkes disease subjects. The clinical trial results demonstrated an early 80.00% reduction in the risk of death compared to untreated historical controls.

Survival Metric:	CUTX-101 Early Treatment	Historical Control
Median Overall Survival:	177.10 months	16.10 months
Risk Reduction:	80.00%	-

Market Significance and Disease Impact

If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease, a rare X-linked recessive pediatric genetic disease. The condition impacts an estimated 1 in 34,810 to as high as 1 in 8,664 live male births and is characterized by distinctive clinical features including sparse and depigmented hair, connective tissue problems, and severe neurological symptoms.

This FDA acceptance brings the potential first treatment for Menkes disease closer to approval, offering hope for patients and families affected by this rare condition.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.09%	+1.14%	-5.57%	-11.36%	-0.81%	+100.30%

Zydus Lifesciences Limited , a prominent player in the pharmaceutical industry, has successfully secured overwhelming shareholder approval for its ambitious ₹5,000 crore fundraising initiative through a postal ballot process conducted on December 12, 2025.

Postal Ballot Results

The company announced comprehensive results of its postal ballot exercise, with shareholders demonstrating strong confidence in the fundraising proposal. The voting was conducted entirely through remote e-voting in compliance with the Companies Act, 2013 and relevant regulatory guidelines.

Voting Details:	Results
Total Valid Votes:	92,41,41,736
Votes in Favor:	92,31,41,736 (99.89%)
Votes Against:	9,91,084 (0.11%)
Voting Method:	Remote e-voting only

The remote e-voting period was conducted from November 13, 2025 (9:00 AM IST) to December 12, 2025 (5:00 PM IST), with Mr. Ashish Doshi of SPANJ Associates serving as the appointed scrutinizer for the voting process. The postal ballot notice was circulated to shareholders on November 11, 2025, with the cut-off date set as November 7, 2025.

Approved Fundraising Framework

The special resolution approved by shareholders provides comprehensive authorization for the Board of Directors to raise funds through multiple instruments and methods. The approved framework allows for significant flexibility in execution.

Fundraising Parameters:	Details
Maximum Amount:	₹5,000 crores
Securities Types:	Equity shares, non-convertible debentures with warrants, convertible securities
Issuance Methods:	QIP, rights issue, preferential allotment, private placement
Completion Timeline:	Within 365 days from resolution date

Fund Utilization Strategy

The company has outlined a strategic approach for utilizing the raised funds, focusing on strengthening its financial position and supporting growth initiatives across multiple areas.

Fund Utilization:	Purpose
Debt Management:	Prepayment of outstanding borrowings
Growth Initiatives:	Organic and inorganic expansion opportunities
Capital Investment:	Infrastructure and facility expansion
General Purposes:	As permitted under applicable laws

NMPA Approval in China

In addition to the fundraising success, Zydus Lifesciences has received approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg strengths. This marks the company's first approval from the NMPA in China, potentially opening up new market opportunities.

Product Details:	Specifications
Product:	Venlafaxine ER Capsules
Strengths:	75 mg and 150 mg
Manufacturing Facility:	Moraiya, Ahmedabad
Market:	China (First NMPA approval)

Venlafaxine ER Capsules are indicated for treating Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The medication works by restoring the balance of serotonin and norepinephrine in the brain.

These developments showcase Zydus Lifesciences' commitment to expanding its financial capabilities and global market presence, positioning the company for future growth and innovation in the pharmaceutical sector.